Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Commentary & Opinion

Participation of Big Pharma Companies Critical to Success of Drug Patent Pools

April 10, 2012

In this post in the Huffington Post's "Impact" blog, David de Ferranti, president of the Results for Development Institute, and Robert Hecht, managing director at the Institute, examine whether patent pools could help increase access to AIDS drugs among the world's poor, writing, "AIDS program managers and advocates must pursue all measures that can keep the cost of treatment low and affordable. In addition to the actions that are already being taken -- like having African governments and donors buy AIDS drugs in bulk from suppliers in order to obtain better prices -- could a 'patent pool' for new drugs help to make AIDS treatment more accessible?"

They highlight the Medicines Patent Pool (MPP), created by UNITAID in 2010 in response to intellectual property (IP) laws enacted in 2005 that "requir[e] countries like India, which previously allowed its generic companies to 'copy' drugs that were patented abroad, to accept patent applications for medicines, including those for AIDS treatment." They write, "The key to a successful MPP is persuading a critical mass of drug companies to join," adding, "The reaction to the MPP from industry so far has been lukewarm," with only one multinational, Gilead, joining the pool. They conclude, "As of today, the history of the MPP is still being written. It will be important to see over the coming year whether this patent pool will become large enough to effectively accelerate the production of low-cost generic versions of new AIDS drugs and the creation of the fixed-dose combination. ... We think the patent pool can be good for everyone involved -- AIDS patients, poor country governments, AIDS donor organizations, and drug companies" (4/9).

Back to other news for April 2012


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More on HIV Drug Patent Policies
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement